Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study

Journal of Clinical Oncology

Volumn 34, Issue 19, 2016, Pages 2258-2264

  Segelov, Eva ^a   Thavaneswaran, Subotheni ^b   Waring, Paul M ^d   Desai, Jayesh ^e   Robledo, Kristy P ^b   Gebski, Val J ^b   Elez, Elena ^m   Nott, Louise M ^h   Karapetis, Christos S ⁱ   Lunke, Sebastian ^d   Chantrill, Lorraine A ^c   Pavlakis, Nick ^b   Khasraw, Mustafa ^b   Underhill, Craig ^k   Ciardiello, Fortunato ⁿ   Jefford, Michael ^e   Wasan, Harpreet ^o   Haydon, Andrew ^f   Price, Timothy J ^j   Van Hazel, Guy ^l   Wilson, Kate ^b   Simes, John ^b   Shapiro, Jeremy D ^g   more..

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g CABRINI HOSPITAL   (Australia)

^h ROYAL HOBART HOSPITAL   (Australia)

ⁱ FLINDERS UNIVERSITY   (Australia)

^j QUEEN ELIZABETH HOSPITAL   (Australia)

^k Border Medical Oncology Australia   (Australia)

^l SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IRINOTECAN; K RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ACNE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRY SKIN; ERYTHEMA MULTIFORME; ERYTHRODERMA; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LOADING DRUG DOSE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PATIENT PREFERENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; PURPURA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH ACNEIFORM; REFRACTORY METASTATIC COLORECTAL CANCER; SKIN INDURATION; SKIN PAIN; TREATMENT RESPONSE; URTICARIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS P21(RAS); QUALITY OF LIFE;

EID: 84976351874     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.6843     Document Type: Article

References (29)

1. World Cancer Research Fund/American Institute for Cancer Research (AICR): Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC, AICR, 2007
2. Boyle P, Langman JS: ABC of colorectal cancer: Epidemiology. BMJ 321:805-808, 2000
3. Bokemeyer C, Köhne CH, Ciardiello F, et al: FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51:1243-1252, 2015
4. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034, 2013
5. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
6. Tejpar S, Celik I, Schlichting M, et al: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570-3577, 2012
7. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006
8. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6:279-286, 2005
9. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648, 2007
10. Gonçalves A, Esteyries S, Taylor-Smedra B, et al: A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximabbased treatment. BMC Cancer 8:169, 2008
11. Morelli MP, Kopetz S: Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30: 3565-3567, 2012
12. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
13. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008
14. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
16. National Cancer Institute, Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) v4.0, 2009. http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ ctc.htm
17. Ward WL, Hahn EA, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 8:181-195, 1999
18. Functional Assessment of Chronic Illness Therapy (FACIT): Questionnaires. FACIT.org, 2009
19. Cardiff University: Department of Dermatology Quality of Life Questionnaires: Dermatology Life Quality Index (DLQI). 1994
20. Clark TG, Altman DG, De Stavola BL: Quantification of the completeness of follow-up. Lancet 359:1309-1310, 2002
21. Kumar SS, Price TJ, Mohyieldin O, et al: KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointest Cancer Res 7:23-26, 2014
22. Messner I, Cadeddu G, Huckenbeck W, et al: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol 139: 201-209, 2013
23. Schirripa M, Loupakis F, Lonardi S, et al: Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol 26: 2503, 2015
24. JonkerDJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
25. Peeters M, Douillard JY, Van Cutsem E, et al: Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: Assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31:759-765, 2013
26. Price TJ, Peeters M, Kim TW, et al: Panitumumab versus cetuximab in patients with chemotherapyrefractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, openlabel, non-inferiority phase 3 study. Lancet Oncol 15: 569-579, 2014
27. Mao C, Huang YF, Yang ZY, et al: KRAS p. G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: A systematic review and meta-analysis. Cancer 119: 714-721, 2013
28. Osumi H, Shinozaki E, Osako M, et al: Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Mol Clin Oncol 3:1053-1057, 2015
29. Siravegna G, Mussolin B, Buscarino M, et al: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 795-801, 2015